PURPOSE: To test the efficacy and safety of the novel antitumor agent MGI-114 (NSC 683863) in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy. METHODS: A two-stage accrual design was used to ensure detection of a true response rate of at least 20% with a type I error of .04. Eligible patients received 11 mg/m2 daily for five consecutive days. Cycles were repeated every 28 days. RESULTS: Fifteen patients received a total of 34 cycles of MGI-114. All patients had a performance status of 0 or 1. Eleven patients had previously received carboplatin and paclitaxel +/- radiation. Two patients had received cisplatin and CPT-11, one patient had received weekly paclitaxel, and one patient had received carboplatin and docetaxel. None of the first 15 patients enrolled experienced objective tumor response, and the study was closed. Forty percent of patients developed > or = grade 2 thrombocytopenia. Grade 3 nausea and > or = grade 2 vomiting were observed in 40% and 47% of patients respectively. Thirty-three percent of patients experienced > or = grade 2 fatigue. CONCLUSIONS: MGI-114, at this dose and schedule, does not have significant activity as second line therapy for patients with advanced NSCLC.
PURPOSE: To test the efficacy and safety of the novel antitumor agent MGI-114 (NSC 683863) in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy. METHODS: A two-stage accrual design was used to ensure detection of a true response rate of at least 20% with a type I error of .04. Eligible patients received 11 mg/m2 daily for five consecutive days. Cycles were repeated every 28 days. RESULTS: Fifteen patients received a total of 34 cycles of MGI-114. All patients had a performance status of 0 or 1. Eleven patients had previously received carboplatin and paclitaxel +/- radiation. Two patients had received cisplatin and CPT-11, one patient had received weekly paclitaxel, and one patient had received carboplatin and docetaxel. None of the first 15 patients enrolled experienced objective tumor response, and the study was closed. Forty percent of patients developed > or = grade 2 thrombocytopenia. Grade 3 nausea and > or = grade 2 vomiting were observed in 40% and 47% of patients respectively. Thirty-three percent of patients experienced > or = grade 2 fatigue. CONCLUSIONS:MGI-114, at this dose and schedule, does not have significant activity as second line therapy for patients with advanced NSCLC.
Authors: F Cardenal; M P López-Cabrerizo; A Antón; V Alberola; B Massuti; A Carrato; I Barneto; M Lomas; M García; P Lianes; J Montalar; C Vadell; J L González-Larriba; B Nguyen; A Artal; R Rosell Journal: J Clin Oncol Date: 1999-01 Impact factor: 44.544
Authors: M Hidalgo; E Izbicka; S G Eckhardt; J R MacDonald; C Cerna; L Gomez; E K Rowinsky; S D Weitman; D D Von Hoff Journal: Anticancer Drugs Date: 1999-10 Impact factor: 2.248
Authors: J R MacDonald; C C Muscoplat; D L Dexter; G L Mangold; S F Chen; M J Kelner; T C McMorris; D D Von Hoff Journal: Cancer Res Date: 1997-01-15 Impact factor: 12.701
Authors: M J Kelner; T C McMorris; L Estes; M Rutherford; M Montoya; J Goldstein; K Samson; R Starr; R Taetle Journal: Biochem Pharmacol Date: 1994-07-19 Impact factor: 5.858